arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Taysha Gene Therapies, Inc.

TSHA
$4.08 ▼ -0.29 (-6.53%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
28 Visible periods
28 Metrics
Peer-ranked Benchmarks
Price Chart
36
Health
Weak
Bearish
auto_awesome

Analytical Summary

Taysha Gene Therapies, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $1.5B
Dividend Yield —
Revenue Growth N/M
Op. Margin None
ROIC -8.6% ↗
FCF / Share $-0.11 →
Trailing P/E —
Price / Book 3.4x
FCF Yield —
Debt / Equity 0.13
info Valuation on last close. End-of-day price, Nov 5, 2026.

28-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$0.00
— —
Net Income Profit after all expenses
$-46.64M
↓ -73.5% —
Operating Margin Operating profit as % of sales
-450.8%
↓ -31.7% —
FCF / Share Free cash flow per share
$-0.11
↑ +1.8% —
Long-Term Debt Long-term obligations
$49.26M
↑ +0.6% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↓
18
Financial Health →
48
Cash Quality ↑
58

bar_chart Data from SEC EDGAR XBRL filings

Synced 5 days ago 7 years · 28 quarters